NALP3 antibody

Background of NALP3 antibody

NLRP3/LP3 belongs to the NLR family of inte immune cytoplasmic receptors (reviewed in De rdo and Latz, 2011; Kanneganti, 2010; And, 2011). NLR family members contain an N-terminus effector region consisting of either a pyrin (PYD), a CARD, or a BIR domain. NLRs also have an intermediate conserved NOD domain and a C-terminus LRR domain. NLRs, like TLRs, alert the immune system to the presence of PAMPs and DAMPs. Like a number of other NLRs, NLRP3 functions in a multiprotein complex called the inflammasome. The inclusion of a particular NLR within an inflammasome depends upon the upstream trigger. The NLRP3 inflammasome is considered to be a global sensor and assembles in response to a broad spectrum of PAMPs and DAMPs. For example, helmith, bacteria, plasmodium and viruses have all been shown to activate NLRP3 (reviewed in Menu and Vince, 2011). The PYD of activated NLRP3 associates with the PYD of ASC, triggering the CARD of ASC to associate with the CARD of caspase-1 and completes the assembly of the NLRP3 inflammasome. This serves as a platform for caspase-1 activation. Activation of NLRP3 can be inhibited by glybenclamide (also known as glyburide) (reviewed in Lamkanfi et al, 2009). Glybenclamide is an ATP-sensitive potassion channel inhibitor that has been shown to inhibit various biological processes including activation of the NRLP3 inflammasome. Glybenclamide is thought to act downstream of the P2X7 receptor but upsteam of NLRP3. Glybenclamide blocks activation of caspase-1 and IL-1beta K+ efflux inhibition. Glybenclamide has a number of additiol functions besides blocking including enhancing insulin action and stimulating synthesis of glucose transporters. Researchers are encouraged to consult the published literature regarding additiol information about how glybenclamide perturbs biological processes.